SEC Form SC 13G filed by Allogene Therapeutics Inc.

7/10/23 10:20:11 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ALLO alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 ALLOGENE THERAPEUTICS INC COMMON STOCK Cusip #019770106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #019770106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 24,917,914 Item 6: 0 Item 7: 24,917,955 Item 8: 0 Item 9: 24,917,955 Item 11: 17.085% Item 12: HC Cusip #019770106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 24,917,955 Item 8: 0 Item 9: 24,917,955 Item 11: 17.085% Item 12: IN Item 1(a). Name of Issuer: ALLOGENE THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 210 EAST GRAND AVENUE South San Francisco, CA 94080 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 019770106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 24,917,955 (b) Percent of Class: 17.085% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 24,917,955 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ALLOGENE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of ALLOGENE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. July 7, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on July 7, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ALLOGENE THERAPEUTICS INC at June 30, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ALLO alert in real time by email

Recent Analyst Ratings for

$ALLO

Date	Price Target	Rating	Analyst
3/14/2025	$5.00	Mkt Perform → Mkt Outperform	Citizens JMP
8/8/2024	$13.00 → $11.00	Outperform	Oppenheimer
5/31/2024	$11.00	Overweight	Piper Sandler
1/5/2024		Mkt Outperform → Mkt Perform	JMP Securities
1/5/2024		Buy → Neutral	Guggenheim
12/8/2023	$7.00	Buy	Citigroup
12/8/2023		Buy	Citigroup
6/26/2023	$28.00	Outperform	Oppenheimer

More analyst ratings

SEC Form SC 13G filed by Allogene Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $ALLO

$ALLO Leadership Updates

Live Leadership Updates

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

Allogene Therapeutics Appoints Earl Douglas as General Counsel

$ALLO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Belldegrun Arie was granted 344,828 shares and bought $4,999,997 worth of shares (1,724,137 units at $2.90) (SEC Form 4)

Parker Geoffrey M. bought $683 worth of shares (190 units at $3.60), increasing direct ownership by 0.02% to 819,590 units (SEC Form 4)

$ALLO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, Finance Yoshiyama Annie sold $13,537 worth of shares (9,601 units at $1.41), decreasing direct ownership by 7% to 130,663 units (SEC Form 4)

President and CEO Chang David D sold $91,469 worth of shares (46,668 units at $1.96), decreasing direct ownership by 0.88% to 5,276,569 units (SEC Form 4)

SVP, Chief Technical Officer Beneski Benjamin Machinas sold $10,839 worth of shares (5,488 units at $1.98), decreasing direct ownership by 2% to 218,507 units (SEC Form 4)

$ALLO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Allogene Therapeutics Inc.

SEC Form SC 13G filed by Allogene Therapeutics Inc.

SEC Form SC 13G/A filed by Allogene Therapeutics Inc. (Amendment)

$ALLO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Allogene upgraded by Citizens JMP with a new price target

Oppenheimer resumed coverage on Allogene with a new price target

Piper Sandler initiated coverage on Allogene with a new price target

$ALLO SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Allogene Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Allogene Therapeutics Inc.

SEC Form 144 filed by Allogene Therapeutics Inc.

$ALLO Financials

Live finance-specific insights

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

$ALLO Press Releases

Fastest customizable press release news feed in the world

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Recent Analyst Ratings for
$ALLO

$ALLO
Leadership Updates

$ALLO
Insider Purchases

$ALLO
Insider Trading

$ALLO
Large Ownership Changes

$ALLO
Analyst Ratings

$ALLO
SEC Filings

$ALLO
Financials

$ALLO
Press Releases